Cerebrospinal Fluid Aβ43 Is Reduced in Early-Onset Compared to Late-Onset Alzheimer’s Disease, But Has Similar Diagnostic Accuracy to Aβ42
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Background Amyloid beta 1-43 (Aβ43) may be a useful additional biomarker for diagnosing Alzheimer’s disease (AD). We have investigated cerebrospinal fluid (CSF) levels of Aβ43 in patients with early-onset AD in contrast to levels in late-onset AD. For comparison, in addition to the ‘core’ biomarkers, several other analytes were also determined (YKL-40, neurofilament light (NF-L), glial fibrillary acidic protein (GFAP), and progranulin). Material and Methods CSF samples were obtained from patients with early-onset AD (age≤62, n=66), late-onset AD (age≥68, n=25), and groups of cognitively intact individuals (age≤62, n=41, age≥68, n=39). Core CSF AD biomarkers (amyloid beta 1-42 (Aβ42), total tau, phosphorylated tau) were analyzed, as well as levels of Aβ43 and other analytes, using commercially-available enzyme-linked immunosorbent assays. Results CSF Aβ43 was significantly reduced in early-onset AD compared to late-onset AD (14.8 ± 7.3 vs. 21.8 ± 9.4 pg/ml respectively), whereas the levels of Aβ42 in the two AD groups were not significantly different (474.9 ± 142.0 vs. 539.6 ± 159.9 pg/ml respectively). Aβ43 and all core biomarkers were significantly altered in patients with AD compared to corresponding controls. NF-L was significantly increased in early-onset AD compared to younger controls, an effect not found between the older groups. Relationships between the Aβ peptides and tau proteins, YKL-40, NF-L, GFAP and progranulin were also investigated without finding marked associations. However, age-associated increases in levels of tau proteins, YKL-40, NF-L and GFAP were found with respect to age in healthy controls. Results for these other analytes were similar to previously published data. Aβ43 did not improve diagnostic accuracy in either AD group compared to Aβ42. Discussion CSF Aβ43, but not Aβ42 levels, varied significantly with age in patients with AD. If CSF levels of Aβ peptides reflect amyloid deposition in brain, the possibility arises that there is a difference between Aβ43 and Aβ42 deposition in younger compared to older brain. However, the level of Aβ43 in CSF shows no improvement over Aβ42 regarding diagnostic accuracy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Olsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., Hölttä, M., Rosén, C., Olsson, C., Strobel, G., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00070-3 · Cited by 2,049
Hansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70355-6 · Cited by 1,700 · cited 1×
“In healthy individuals, several studies have found little or no correlation between age and Aβ42 levels in CSF (Hansson et al., 2006; Bouwman et al., 2009; Mattsson et al., 2009; Popp et al., 2010).”
BackgroundInverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ 42 in humans
Fagan, A. M., Mintun, M. A., Mach, R. H., Lee, S., Dence, C. S., Shah, A. R., LaRossa, G. N., Spinner, M. L., Klunk, W. E., Mathis, C. A., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20730 · Cited by 1,246
CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment
Mattsson, N. (2009) · JAMA · doi:10.1001/jama.2009.1064 · Cited by 1,176
Age, Neuropathology, and Dementia
Savva, G. M., Wharton, S. B., Ince, P. G., Forster, G., Matthews, F. E., & Brayne, C. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0806142 · Cited by 900
YKL-40: A Novel Prognostic Fluid Biomarker for Preclinical Alzheimer's Disease
Craig-Schapiro, R., Perrin, R. J., Roe, C. M., Xiong, C., Carter, D., Cairns, N. J., Mintun, M. A., Peskind, E. R., Li, G., Galasko, D. R., et al. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.08.025 · Cited by 504
Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease
Alcolea, D., Martínez-Lage, P., Sánchez-Juan, P., Olazarán, J., Antúnez, C., Izagirre, A., Ecay-Torres, M., Estanga, A., Clerigué, M., Guisasola, M. C., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001859 · Cited by 163
Early-onset Alzheimer’s disease is associated with greater pathologic burden.
Marshall, G. A., Fairbanks, L. A., Tekin, S., Vinters, H. V., & Cummings, J. L. (2007) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988706297086 · Cited by 143
Amyloid burden and metabolic function in early-onset Alzheimer’s disease: parietal lobe involvement.
Ossenkoppele, R., Zwan, M. D., Tolboom, N., van Assema, D. M. E., Adriaanse, S. F., Kloet, R. W., Boellaard, R., Windhorst, A. D., Barkhof, F., Lammertsma, A. A., et al. (2012) · Brain · doi:10.1093/brain/aws113 · Cited by 123
Cited by
Current state of Alzheimer’s fluid biomarkers
Molinuevo, J. L., Ayton, S., Batrla, R., Bednar, M. M., Bittner, T., Cummings, J., Fagan, A. M., Hampel, H., Mielke, M. M., Mikulskis, A., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1932-x · Cited by 518
Early-onset Alzheimer Disease and Its Variants
Mendez, M. F. (2019) · Continuum · doi:10.1212/con.0000000000000687 · Cited by 307
Astrocyte Biomarkers in Alzheimer Disease: A Systematic Review and Meta-analysis
Bellaver, B., Ferrari-Souza, J. P., Uglione da Ros, L., Carter, S. F., Rodriguez-Vieitez, E., Nordberg, A., Pellerin, L., Rosa-Neto, P., Leffa, D. T., & Zimmer, E. R. (2021) · Neurology · doi:10.1212/wnl.0000000000012109 · Cited by 123
“Table 1 Description of Included Studies Article Subjects, n Age ± SD (range), y Male, % Diagnosis criteria Astrocyte biomarker Fluid/imaging Detection methodCU AD CU AD CU AD Alcolea et al.32 24 59 64 (57–69) 71 (64–77) 55.7 45.8 NINCDS-ADRDA14 YKL-40 CSF ELISA Andreasen et al.43 19 35 71.2 ± 7.3 72.1 ± 5.9 ND ND NINC…”
BackgroundInfluentialIncreased GFAP concentrations in the cerebrospinal fluid of patients with unipolar depression
Michel, M., Fiebich, B. L., Kuzior, H., Meixensberger, S., Berger, B., Maier, S., Nickel, K., Runge, K., Denzel, D., Pankratz, B., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01423-6 · Cited by 79
Giannisis, A., Al-Grety, A., Carlsson, H., Patra, K., Twohig, D., Sando, S. B., Lauridsen, C., Berge, G., Grøntvedt, G. R., Bråthen, G., et al. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-022-01058-9 · Cited by 46
Self-citation
Metadata
- Authors
- Lauridsen, C., Sando, S. B., Møller, I., Berge, G., Pomary, P. K., Grøntvedt, G. R., Salvesen, Ø., Bråthen, G., & White, L. R.
- Venue
- Frontiers in Aging Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2017-06-28
- Volume
- 9
- Pages
- 210-210
- ISSN
- 1663-4365 (ISSN-L)
- OpenAlex
- W2733497613
- Cited by
- 26
- References
- 11
- FWCI
- 1.79
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cerebrospinal Fluid Aβ43 Is Reduced in Early-Onset Compared to Late-Onset Alzheimer’s Disease, But Has Similar Diagnostic Accuracy to Aβ42. https://app.cochat.ai/papers/10.3389/fnagi.2017.00210
- The paper
- Lauridsen, C., Sando, S. B., Møller, I., Berge, G., Pomary, P. K., Grøntvedt, G. R., Salvesen, Ø., Bråthen, G., & White, L. R. (2017). Cerebrospinal Fluid Aβ43 Is Reduced in Early-Onset Compared to Late-Onset Alzheimer’s Disease, But Has Similar Diagnostic Accuracy to Aβ42. Frontiers in Aging Neuroscience. https://doi.org/10.3389/fnagi.2017.00210
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.